Unknown OBSERVATIONAL NCT03458624

Long-term Observational Study to Evalution the Safety and Efficacy of FURESTEM-AD Inj.

Observational Study to Evaluate the Safety and Efficacy of FURESTEM-AD Inj. in Moderate to Severe Atopic Dermatitis Patients Who Participated in Phase 1/2a Clinical Trial of FURESTEM-AD Lnj.

Sponsor: Kang Stem Biotech Co., Ltd.

Conditions Atopic Dermatitis

Updated 8 times since 2018 Last updated: Mar 7, 2018 Started: Jul 1, 2016 Primary completion: Aug 12, 2016 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03458624, this observational or N/A phase trial focuses on Atopic Dermatitis and remains ongoing. Sponsored by Kang Stem Biotech Co., Ltd., it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Unknown
Sep 2024 — Sep 2025 [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Mar 2020 — Jan 2021 [monthly]

Unknown Status

Status: Active Not Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Mar 2020 [monthly]

Active Not Recruiting
Apr 2018 — Jun 2018 [monthly]

Active Not Recruiting

Phase: NA → None
Mar 2018 — Apr 2018 [monthly]

Active Not Recruiting NA

First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kang Stem Biotech Co., Ltd.

Data source: Kang Stem Biotech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea